Schizophrenia is a debilitating mental illness which involves three groups of symptoms, ie,
positive, negative and cognitive, and has major public health implications. According to …

Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia,
bipolar disorders and other psychotic disorders. However, they might cause metabolic …

The introduction of atypical antipsychotics (AAPs) since the discovery of its prototypical drug
clozapine has been a revolutionary pharmacological step for treating psychotic patients as …

Almost fifty years after its first introduction into clinical care, clozapine remains the only
evidence-based pharmacological option for treatment-resistant schizophrenia (TRS), which …

Clozapine is superior to other antipsychotics as a therapy for treatment-resistant
schizophrenia and schizoaffective disorder with increased risk of suicidal behavior. This …

Mood disorders remain a major public health concern worldwide. Monoaminergic
hypotheses of pathophysiology of bipolar and major depressive disorders have led to the …

Schizophrenia is a severe psychiatric illness affecting almost 25 million people worldwide
and is conceptualized as a disorder of synaptic plasticity and brain connectivity …

Objectives Clozapine (CLZ) is prescribed to (relatively) treatment-resistant patients with
schizophrenia spectrum disorders. Currently, it is unknown what factors predict response to …

Several atypical antipsychotics exert mood-stabilising effects via the modulation of various
monoamine receptors and intracellular signallings. Recent pharmacodynamic studies …

Clozapine (CLZ) is an approved antipsychotic agent for the medication of treatment-resistant
schizophrenia but is also well known as one of the most toxic antipsychotics. Recently, the …